Skip to main content
Top
Gepubliceerd in: Quality of Life Research 7/2012

01-09-2012

Health-related quality of life changes associated with buprenorphine treatment for opioid dependence

Auteurs: Dennis W. Raisch, Heather M. Campbell, David A. Garnand, Mark A. Jones, Mike R. Sather, Rupali Naik, Walter Ling

Gepubliceerd in: Quality of Life Research | Uitgave 7/2012

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Background

Few studies have described improvement in health-related quality of life (HRQOL) associated with opioid dependence treatment with buprenorphine (ODT-B).

Objective

To evaluate HRQOL changes in domain scores, physical and mental component summaries, and health utilities (HUs) associated with ODT-B using the Short Form 36 (SF-36).

Methods

We assessed HRQOL changes in a substudy of a pharmacokinetic study that compared buprenorphine oral tablet and liquid dosage formulations over 16 weeks. Individuals, aged 18–65 years, were screened for opioid dependence. They were excluded if they would not agree to birth control or had a serious medical condition. Subjects received psychosocial counseling and weekly group therapy. The SF-36 was administered upon enrollment and at 4-week intervals. We used the SF-6D to estimate HUs. We performed intention to treat (ITT) analyses based on the last observation available for each subject. Paired t tests of each domain and HU, limited to remaining patients at each 4-week interval, were also conducted.

Results

Of 96 subjects enrolled, cumulative dropouts over time resulted in 80, 69, 59, and 44 subjects remaining at 4, 8, 12, and 16 weeks. There were no significant differences in opioid-positive urines, dropout rates, or dosage changes between formulations. In the ITT analyses, HRQOL improvements over time were bodily pain (62.1 vs. 69.1, P = 0.017), vitality (49.8 vs. 56.5, P = 0.001), mental health (59.9 vs. 66.0, P = 0.001), social function (66.4 vs. 74.7, P = 0.001), role emotional (59.4 vs. 71.9, P = 0.003), role physical (60.9 vs. 70.6, P = 0.005), and mental component summary (41.9 vs. 45.4, P<0.001). HU scores also improved (0.674 vs. 0.715, P = 0.001). Results from paired t tests, with only concurrently enrolled patients, showed similar improvements from baseline to 4, 8, 12, or 16 weeks.

Conclusion

Buprenorphine, accompanied with psychosocial counseling, was associated with improved HRQOL and HUs.
Literatuur
1.
go back to reference Ling, W., & Wesson, D. R. (2003). Clinical efficacy of buprenorphine comparisons to methadone and placebo. Drug and Alcohol Dependence, 70(2), S49–S57.PubMedCrossRef Ling, W., & Wesson, D. R. (2003). Clinical efficacy of buprenorphine comparisons to methadone and placebo. Drug and Alcohol Dependence, 70(2), S49–S57.PubMedCrossRef
2.
go back to reference Fudala, P. J., Bridge, T. P., Herbert, S., et al. (2003). Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine, 349(10), 949–958.PubMedCrossRef Fudala, P. J., Bridge, T. P., Herbert, S., et al. (2003). Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine, 349(10), 949–958.PubMedCrossRef
3.
go back to reference Clark, H. W. (2001). A new era in opioid dependency treatment. Recent law allows qualified physicians to provide care in office setting. Postgrad Med, 109(6), 15–16, 25. Clark, H. W. (2001). A new era in opioid dependency treatment. Recent law allows qualified physicians to provide care in office setting. Postgrad Med, 109(6), 15–16, 25.
4.
go back to reference Raisch, D. W., Fye, C. L., Boardman, K. D., & Sather, M. R. (2002). Opioid dependence treatment, including buprenorphine/naloxone. Annals of Pharmacotherapy, 36, 312–321.PubMedCrossRef Raisch, D. W., Fye, C. L., Boardman, K. D., & Sather, M. R. (2002). Opioid dependence treatment, including buprenorphine/naloxone. Annals of Pharmacotherapy, 36, 312–321.PubMedCrossRef
5.
go back to reference Connock, M., Juarez-Garcia, A., Jowett, S., et al. (2007). Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technology Assessment, 11(9), 1–190.PubMed Connock, M., Juarez-Garcia, A., Jowett, S., et al. (2007). Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technology Assessment, 11(9), 1–190.PubMed
6.
go back to reference Donaher, P. A., & Welsh, C. (2006). Managing opioid addiction with buprenorphine. American Family Physician, 73(9), 1573–1578.PubMed Donaher, P. A., & Welsh, C. (2006). Managing opioid addiction with buprenorphine. American Family Physician, 73(9), 1573–1578.PubMed
7.
go back to reference Ling, W., & Smith, D. (2002). Buprenorphine: blending practice and research. J Subst Abuse Treat, 23(2), 87–92.PubMedCrossRef Ling, W., & Smith, D. (2002). Buprenorphine: blending practice and research. J Subst Abuse Treat, 23(2), 87–92.PubMedCrossRef
8.
go back to reference Torrington, M., Domier, C. P., Hillhouse, M., & Ling, W. (2007). Buprenorphine 101: treating opioid dependence with buprenorphine in an office-based setting. Journal of Addictive Diseases, 26(3), 93–99.PubMedCrossRef Torrington, M., Domier, C. P., Hillhouse, M., & Ling, W. (2007). Buprenorphine 101: treating opioid dependence with buprenorphine in an office-based setting. Journal of Addictive Diseases, 26(3), 93–99.PubMedCrossRef
9.
go back to reference Bell, J., Shanahan, M., Mutch, C., et al. (2007). A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction, 102(12), 1899–1907.PubMedCrossRef Bell, J., Shanahan, M., Mutch, C., et al. (2007). A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction, 102(12), 1899–1907.PubMedCrossRef
10.
go back to reference Barnett, P. G., Rodgers, J. H., & Bloch, D. A. (2001). A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction, 96(5), 683–690.PubMedCrossRef Barnett, P. G., Rodgers, J. H., & Bloch, D. A. (2001). A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction, 96(5), 683–690.PubMedCrossRef
11.
go back to reference Harris, A. H., Gospodarevskaya, E., & Ritter, A. J. (2005). A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics, 23(1), 77–91.PubMedCrossRef Harris, A. H., Gospodarevskaya, E., & Ritter, A. J. (2005). A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics, 23(1), 77–91.PubMedCrossRef
12.
go back to reference Doran, C. M., Shanahan, M., Mattick, R. P., Ali, R., White, J., & Bell, J. (2003). Buprenorphine versus methadone maintenance a cost-effectiveness analysis. Drug and Alcohol Dependence, 71(3), 295–302.PubMedCrossRef Doran, C. M., Shanahan, M., Mattick, R. P., Ali, R., White, J., & Bell, J. (2003). Buprenorphine versus methadone maintenance a cost-effectiveness analysis. Drug and Alcohol Dependence, 71(3), 295–302.PubMedCrossRef
13.
go back to reference Giacomuzzi, S. M., Riemer, Y., Ertl, M., et al. (2003). Buprenorphine versus methadone maintenance treatment in an ambulant setting a health-related quality of life assessment. Addiction, 98(5), 693–702.PubMedCrossRef Giacomuzzi, S. M., Riemer, Y., Ertl, M., et al. (2003). Buprenorphine versus methadone maintenance treatment in an ambulant setting a health-related quality of life assessment. Addiction, 98(5), 693–702.PubMedCrossRef
14.
go back to reference Maremmani, I., Pani, P. P., Pacini, M., & Perugi, G. (2007). Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J Subst Abuse Treat, 33(1), 91–98.PubMedCrossRef Maremmani, I., Pani, P. P., Pacini, M., & Perugi, G. (2007). Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J Subst Abuse Treat, 33(1), 91–98.PubMedCrossRef
15.
go back to reference Smith, K. W., & Larson, M. J. (2003). Quality of life assessments by adult substance abusers receiving publicly funded treatment in Massachusetts. American Journal of Drug and Alcohol Abuse, 29(2), 323–335.PubMedCrossRef Smith, K. W., & Larson, M. J. (2003). Quality of life assessments by adult substance abusers receiving publicly funded treatment in Massachusetts. American Journal of Drug and Alcohol Abuse, 29(2), 323–335.PubMedCrossRef
16.
go back to reference Vanagas, G., Padaiga, Z., & Subata, E. (2004). Drug addiction maintenance treatment and quality of life measurements. Medicina (Kaunas), 40(9), 833–841. Vanagas, G., Padaiga, Z., & Subata, E. (2004). Drug addiction maintenance treatment and quality of life measurements. Medicina (Kaunas), 40(9), 833–841.
17.
go back to reference Torrens, M., San, L., Martinez, A., Castillo, C., Domingo-Salvany, A., & Alonso, J. (1997). Use of the Nottingham health profile for measuring health status of patients in methadone maintenance treatment. Addiction, 92(6), 707–716.PubMedCrossRef Torrens, M., San, L., Martinez, A., Castillo, C., Domingo-Salvany, A., & Alonso, J. (1997). Use of the Nottingham health profile for measuring health status of patients in methadone maintenance treatment. Addiction, 92(6), 707–716.PubMedCrossRef
18.
go back to reference Eklund, C., Melin, L., Hiltunen, A., & Borg, S. (1994). Detoxification from methadone maintenance treatment in Sweden: long-term outcome and effects on quality of life and life situation. Int J Addict, 29(5), 627–645.PubMed Eklund, C., Melin, L., Hiltunen, A., & Borg, S. (1994). Detoxification from methadone maintenance treatment in Sweden: long-term outcome and effects on quality of life and life situation. Int J Addict, 29(5), 627–645.PubMed
19.
go back to reference Reno, R. R., & Aiken, L. S. (1993). Life activities and life quality of heroin addicts in and out of methadone treatment. Int J Addict, 28(3), 211–232.PubMed Reno, R. R., & Aiken, L. S. (1993). Life activities and life quality of heroin addicts in and out of methadone treatment. Int J Addict, 28(3), 211–232.PubMed
20.
go back to reference Millson, P. E., Challacombe, L., Villeneuve, P. J., et al. (2004). Self-perceived health among Canadian opiate users: a comparison to the general population and to other chronic disease populations. Canadian Journal of Public Health, 95(2), 99–103. Millson, P. E., Challacombe, L., Villeneuve, P. J., et al. (2004). Self-perceived health among Canadian opiate users: a comparison to the general population and to other chronic disease populations. Canadian Journal of Public Health, 95(2), 99–103.
21.
go back to reference Calsyn, D. A., Saxon, A. J., Bush, K. R., et al. (2004). The addiction severity index medical and psychiatric composite scores measure similar domains as the SF-36 in substance-dependent veterans: concurrent and discriminant validity. Drug and Alcohol Dependence, 76, 165–171.PubMedCrossRef Calsyn, D. A., Saxon, A. J., Bush, K. R., et al. (2004). The addiction severity index medical and psychiatric composite scores measure similar domains as the SF-36 in substance-dependent veterans: concurrent and discriminant validity. Drug and Alcohol Dependence, 76, 165–171.PubMedCrossRef
22.
go back to reference Brazier, J., Usherwood, T., Harper, R., & Thomas, K. (1998). Deriving a preference-based single index from the UK SF-36 Health Survey. Journal of Clinical Epidemiology, 51(11), 1115–1128.PubMedCrossRef Brazier, J., Usherwood, T., Harper, R., & Thomas, K. (1998). Deriving a preference-based single index from the UK SF-36 Health Survey. Journal of Clinical Epidemiology, 51(11), 1115–1128.PubMedCrossRef
23.
go back to reference Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. J Health Econ, 21(2), 271–292.PubMedCrossRef Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. J Health Econ, 21(2), 271–292.PubMedCrossRef
24.
go back to reference Walters, S. J., & Brazier, J. E. (2003). What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes, 1(1), 4–5.PubMedCrossRef Walters, S. J., & Brazier, J. E. (2003). What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes, 1(1), 4–5.PubMedCrossRef
25.
go back to reference Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.PubMedCrossRef Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.PubMedCrossRef
26.
go back to reference Feeny, D., Furlong, W., Torrance, G. W., et al. (2002). Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Medical Care, 40(2), 113–128.PubMedCrossRef Feeny, D., Furlong, W., Torrance, G. W., et al. (2002). Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Medical Care, 40(2), 113–128.PubMedCrossRef
27.
go back to reference Kaplan, R. M., Ganiats, T. G., Sieber, W. J., & Anderson, J. P. (1998). The quality of well-being scale: Critical similarities and differences with SF-36. International Journal for Quality in Health Care, 10(6), 509–520.PubMedCrossRef Kaplan, R. M., Ganiats, T. G., Sieber, W. J., & Anderson, J. P. (1998). The quality of well-being scale: Critical similarities and differences with SF-36. International Journal for Quality in Health Care, 10(6), 509–520.PubMedCrossRef
28.
go back to reference Compton, P., Ling, W., Moody, D., & Chiang, N. (2006). Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug and Alcohol Dependence, 82(1), 25–31.PubMedCrossRef Compton, P., Ling, W., Moody, D., & Chiang, N. (2006). Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug and Alcohol Dependence, 82(1), 25–31.PubMedCrossRef
29.
go back to reference Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.PubMedCrossRef Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.PubMedCrossRef
30.
go back to reference McHorney, C. A., Ware, J. E., Jr., Lu, J. F., & Sherbourne, C. D. (1994). The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Medical Care, 32(1), 40–66.PubMedCrossRef McHorney, C. A., Ware, J. E., Jr., Lu, J. F., & Sherbourne, C. D. (1994). The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Medical Care, 32(1), 40–66.PubMedCrossRef
31.
go back to reference McHorney, C. A., Ware, J. E., Jr., & Raczek, A. E. (1993). The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care, 31(3), 247–263.PubMedCrossRef McHorney, C. A., Ware, J. E., Jr., & Raczek, A. E. (1993). The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care, 31(3), 247–263.PubMedCrossRef
32.
go back to reference Ware JE, Snow KK, Kosinksi M, Gandek B. SF-36 Health survey manual and interpretation guide. The Health Institute New England Medical Journal, Boston, 1993). Ware JE, Snow KK, Kosinksi M, Gandek B. SF-36 Health survey manual and interpretation guide. The Health Institute New England Medical Journal, Boston, 1993).
33.
go back to reference Hollingworth, W., Sullivan, S. D., Emerson, S. S., Gray, D. T., & Jarvik, J. G. (2002). The practicality and validity of directly elicited and SF-36 derived health state preferences in patients with low back pain. Health Economics, 11, 71–85.PubMedCrossRef Hollingworth, W., Sullivan, S. D., Emerson, S. S., Gray, D. T., & Jarvik, J. G. (2002). The practicality and validity of directly elicited and SF-36 derived health state preferences in patients with low back pain. Health Economics, 11, 71–85.PubMedCrossRef
34.
go back to reference Sherbourne, C. D., Unützer, J., Schoenbaum, M., Duan, N., Lenert, L. A., Sturm, R., et al. (2001). Can utility-weighted health-related quality-of-life estimates capture health effects of quality improvement for depression? Medical Care, 39(11), 1246–1259. Sherbourne, C. D., Unützer, J., Schoenbaum, M., Duan, N., Lenert, L. A., Sturm, R., et al. (2001). Can utility-weighted health-related quality-of-life estimates capture health effects of quality improvement for depression? Medical Care, 39(11), 1246–1259.
35.
go back to reference Pyne, J. M., Rost, K. M., Zhang, M., Williams, D. K., Smith, J., & Fortney, J. (2003). Cost-effectiveness of a primary care depression intervention. Journal of General Internal Medicine, 18, 432–441.PubMedCrossRef Pyne, J. M., Rost, K. M., Zhang, M., Williams, D. K., Smith, J., & Fortney, J. (2003). Cost-effectiveness of a primary care depression intervention. Journal of General Internal Medicine, 18, 432–441.PubMedCrossRef
36.
go back to reference Lobo, F. S., Gross, C. R., & Matthees, B. J. (2004). Estimation and comparison of derived preference scores from the SF-36 in lung transplant patients. Quality of Life Research, 13, 377–388.PubMedCrossRef Lobo, F. S., Gross, C. R., & Matthees, B. J. (2004). Estimation and comparison of derived preference scores from the SF-36 in lung transplant patients. Quality of Life Research, 13, 377–388.PubMedCrossRef
37.
go back to reference Green, C., Brazier, J., & Deverill, M. (2000). Valuing health-related quality of life. A review of health state valuation techniques. Pharmacoeconomics, 17(2), 151–165.PubMedCrossRef Green, C., Brazier, J., & Deverill, M. (2000). Valuing health-related quality of life. A review of health state valuation techniques. Pharmacoeconomics, 17(2), 151–165.PubMedCrossRef
38.
go back to reference Raisch, D. W. (2000). Understanding quality-adjusted life years and their application to pharmacoeconomic research. Annals of Pharmacotherapy, 34(7–8), 906–914.PubMedCrossRef Raisch, D. W. (2000). Understanding quality-adjusted life years and their application to pharmacoeconomic research. Annals of Pharmacotherapy, 34(7–8), 906–914.PubMedCrossRef
39.
go back to reference Mattick, R. P., Ali, R., White, J. M., O’Brien, S., Wolk, S., & Danz, C. (2003). Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction, 98(4), 441–452.PubMedCrossRef Mattick, R. P., Ali, R., White, J. M., O’Brien, S., Wolk, S., & Danz, C. (2003). Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction, 98(4), 441–452.PubMedCrossRef
40.
go back to reference Lintzeris, N., Bell, J., Bammer, G., Jolley, D. J., & Rushworth, L. (2002). A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction, 97(11), 1395–1404.PubMedCrossRef Lintzeris, N., Bell, J., Bammer, G., Jolley, D. J., & Rushworth, L. (2002). A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction, 97(11), 1395–1404.PubMedCrossRef
41.
go back to reference Ling, W., Charuvastra, C., Collins, J. F., et al. (1998). Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction, 93(4), 475–486.PubMedCrossRef Ling, W., Charuvastra, C., Collins, J. F., et al. (1998). Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction, 93(4), 475–486.PubMedCrossRef
42.
go back to reference Ponizovsky, A. M., & Grinshpoon, A. (2007). Quality of life among heroin users on buprenorphine versus methadone maintenance. American Journal of Drug and Alcohol Abuse, 33(5), 631–642.PubMedCrossRef Ponizovsky, A. M., & Grinshpoon, A. (2007). Quality of life among heroin users on buprenorphine versus methadone maintenance. American Journal of Drug and Alcohol Abuse, 33(5), 631–642.PubMedCrossRef
43.
go back to reference Ballantyne, J. C., & LaForge, K. S. (2007). Opioid dependence and addiction during opioid treatment of chronic pain. Pain, 129(3), 235–255.PubMedCrossRef Ballantyne, J. C., & LaForge, K. S. (2007). Opioid dependence and addiction during opioid treatment of chronic pain. Pain, 129(3), 235–255.PubMedCrossRef
44.
go back to reference Miotto, K., Compton, P., Ling, W., & Conolly, M. (1996). Diagnosing addictive disease in chronic pain patients. Psychosomatics, 37(3), 223–235.PubMedCrossRef Miotto, K., Compton, P., Ling, W., & Conolly, M. (1996). Diagnosing addictive disease in chronic pain patients. Psychosomatics, 37(3), 223–235.PubMedCrossRef
45.
go back to reference Wu, S. M., Compton, P., Bolus, R., et al. (2006). The addiction behaviors checklist: validation of a new clinician-based measure of inappropriate opioid use in chronic pain. Journal of Pain and Symptom Management, 32(4), 342–351.PubMedCrossRef Wu, S. M., Compton, P., Bolus, R., et al. (2006). The addiction behaviors checklist: validation of a new clinician-based measure of inappropriate opioid use in chronic pain. Journal of Pain and Symptom Management, 32(4), 342–351.PubMedCrossRef
46.
go back to reference Hatoum, H. T., Brazier, J. E., & Akhras, K. S. (2004). Comparison of the HUI3 with the SF-36 preference based SF-6D in a clinical trial setting. Value Health, 7(5), 602–609.PubMedCrossRef Hatoum, H. T., Brazier, J. E., & Akhras, K. S. (2004). Comparison of the HUI3 with the SF-36 preference based SF-6D in a clinical trial setting. Value Health, 7(5), 602–609.PubMedCrossRef
47.
go back to reference Brazier, J., Roberts, J., Tsuchiya, A., & Busschbach, J. (2004). A comparison of the EQ-5D and SF-6D across seven patient groups. Health Economics, 13(9), 873–884.PubMedCrossRef Brazier, J., Roberts, J., Tsuchiya, A., & Busschbach, J. (2004). A comparison of the EQ-5D and SF-6D across seven patient groups. Health Economics, 13(9), 873–884.PubMedCrossRef
48.
go back to reference Harrison, M. J., Davies, L. M., Bansback, N. J., et al. (2009). The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. Quality of Life Research, 18(9), 1195–1205.PubMedCrossRef Harrison, M. J., Davies, L. M., Bansback, N. J., et al. (2009). The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. Quality of Life Research, 18(9), 1195–1205.PubMedCrossRef
49.
go back to reference Khanna, D., Furst, D. E., Wong, W. K., et al. (2007). Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Quality of Life Research, 16(6), 1083–1092.PubMedCrossRef Khanna, D., Furst, D. E., Wong, W. K., et al. (2007). Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Quality of Life Research, 16(6), 1083–1092.PubMedCrossRef
50.
go back to reference Lee, B. B., King, M. T., Simpson, J. M., et al. (2008). Validity, responsiveness, and minimal important difference for the SF-6D health utility scale in a spinal cord injured population. Value Health, 11(4), 680–688.PubMedCrossRef Lee, B. B., King, M. T., Simpson, J. M., et al. (2008). Validity, responsiveness, and minimal important difference for the SF-6D health utility scale in a spinal cord injured population. Value Health, 11(4), 680–688.PubMedCrossRef
51.
go back to reference Broz, D., & Ouellet, L. J. (2008). Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic. Drug and Alcohol Dependence, 94(1–3), 221–233.PubMedCrossRef Broz, D., & Ouellet, L. J. (2008). Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic. Drug and Alcohol Dependence, 94(1–3), 221–233.PubMedCrossRef
52.
go back to reference Badia, X., Roset, M., Herdman, M., & Kind, P. (2001). A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med Decis Making, 21(1), 7–16.PubMedCrossRef Badia, X., Roset, M., Herdman, M., & Kind, P. (2001). A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med Decis Making, 21(1), 7–16.PubMedCrossRef
53.
go back to reference Gabriel, S. E., Kneeland, T. S., Melton, L. J., 3rd, Moncur, M. M., Ettinger, B., & Tosteson, A. N. (1999). Health-related quality of life in economic evaluations for osteoporosis: Whose values should we use? Med Decis Making, 19(2), 141–148.PubMedCrossRef Gabriel, S. E., Kneeland, T. S., Melton, L. J., 3rd, Moncur, M. M., Ettinger, B., & Tosteson, A. N. (1999). Health-related quality of life in economic evaluations for osteoporosis: Whose values should we use? Med Decis Making, 19(2), 141–148.PubMedCrossRef
54.
go back to reference Huang, I. C., Willke, R. J., Atkinson, M. J., Lenderking, W. R., Frangakis, C., & Wu, A. W. (2007). US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference? Quality of Life Research, 16(6), 1065–1072.PubMedCrossRef Huang, I. C., Willke, R. J., Atkinson, M. J., Lenderking, W. R., Frangakis, C., & Wu, A. W. (2007). US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference? Quality of Life Research, 16(6), 1065–1072.PubMedCrossRef
Metagegevens
Titel
Health-related quality of life changes associated with buprenorphine treatment for opioid dependence
Auteurs
Dennis W. Raisch
Heather M. Campbell
David A. Garnand
Mark A. Jones
Mike R. Sather
Rupali Naik
Walter Ling
Publicatiedatum
01-09-2012
Uitgeverij
Springer Netherlands
Gepubliceerd in
Quality of Life Research / Uitgave 7/2012
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-011-0027-0

Andere artikelen Uitgave 7/2012

Quality of Life Research 7/2012 Naar de uitgave